Oxford BioDynamics Plc (LON:OBD – Get Free Report) reached a new 52-week low on Tuesday . The company traded as low as GBX 0.48 ($0.01) and last traded at GBX 0.50 ($0.01), with a volume of 16868893 shares changing hands. The stock had previously closed at GBX 0.55 ($0.01).
Oxford BioDynamics Stock Performance
The company has a debt-to-equity ratio of 370.22, a quick ratio of 2.80 and a current ratio of 0.68. The company has a market cap of £1.56 million, a P/E ratio of -8.33 and a beta of 0.42. The business has a 50 day moving average price of GBX 1.07 and a two-hundred day moving average price of GBX 3.13.
Oxford BioDynamics Company Profile
Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.
Featured Articles
- Five stocks we like better than Oxford BioDynamics
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- Bank Stocks – Best Bank Stocks to Invest In
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- What Are Earnings Reports?
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Receive News & Ratings for Oxford BioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
